Tourmaline Bio, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Tourmaline Bio, Inc. Tourmaline Bio, Inc. (TRML) operates as a late-stage clinical biotechnology company focused on developing transformative medicines for patients with life-altering inflammatory and immune diseases, including atherosclerotic cardiovascular disease and thyroid eye disease; its lead product candidate is pacibekitug (formerly TOUR006), a fully human monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine implicated in autoimmune and inflammatory disorders. The company targets high unmet medical needs in immunology and inflammation through its pipeline of biologic therapies administered as low-volume, infrequently dosed subcutaneous injections. Founded in 2021 and headquartered at 27 West 24th Street, Suite 702, New York, New York, Tourmaline Bio previously operated as Tourmaline Bio, LLC before changing its name to Tourmaline Bio, Inc. in September 2022; it conducts operations primarily in the United States. In its most significant recent development, Novartis AG completed the acquisition of Tourmaline Bio on October 28, 2025, for $48.00 per share in cash, representing a total equity value of approximately $1.4 billion, after which Tourmaline became an indirect wholly owned subsidiary of Novartis with its shares ceasing to trade on Nasdaq, enabling accelerated advancement of pacibekitug in cardiovascular innovation.
Novartis completes acquisition of Tourmaline Bio
Novartis announces expiration of Tourmaline Bio tender offer
Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer
Tourmaline Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRML
Novartis announces commencement of tender offer to acquire Tourmaline Bio
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Tourmaline Bio, Inc. (NASDAQ: TRML)
TOURMALINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRML
NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline
This Small Biotech Stock Is Surging Today. Here's Why.
Wall Street Breakfast Podcast: Nebius Rockets On $17B Microsoft Deal
TRML Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Tourmaline Bio, Inc. Is Fair to Shareholders
Novartis strikes $1.4bn deal for Tourmaline Bio
Shareholder Alert: The Ademi Firm investigates whether Tourmaline Bio, Inc. is obtaining a Fair Price for its Public Shareholders
Novartis to acquire Tourmaline Bio in deal valuing it at $1.4 billion
Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress
Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know
Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition